Perceptive Advisors’s Crescent Biopharma CBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$10.3M Buy
706,942
+500,000
+242% +$8.38M 0.18% 69
2026
Q2
$3.72M Hold
206,942
– – 0.06% 97
2026
Q1
$3.8M Sell
206,942
-246,744
-54% -$2.83M 0.07% 80
2025
Q4
$5.38M Hold
453,686
– – 0.1% 91
2025
Q3
$5.39M Hold
453,686
– – 0.16% 71
2025
Q2
$7.32M Buy
+453,686
New +$9.6M 0.27% 57

Other funds holding CBIO

Perceptive Advisors's CBIO Position: Q3 2026 in Review

Perceptive Advisors increased its Crescent Biopharma (CBIO) stake by 242% in Q3 2026, buying an estimated $8.38M and bringing the position to 706,942 shares worth $10.3M. The position accounts for 0.18% of the portfolio, ranked #69.

Perceptive Advisors first reported a position in CBIO in Q2 2025 and has held it in 6 quarters since. 104 funds tracked by Wall St. Rank hold CBIO as of Q3 2026.

  • Perceptive Advisors held 706,942 shares of Crescent Biopharma worth $10.3M as of Q3 2026.
  • Perceptive Advisors bought 500,000 Crescent Biopharma shares in Q3 2026, an estimated $8.38M.
  • Crescent Biopharma made up 0.18% of Perceptive Advisors's portfolio in Q3 2026, its #69 holding.
  • Perceptive Advisors first reported a position in Crescent Biopharma in Q2 2025 and has held it in 6 quarters since.
  • 104 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2026.

Based on Perceptive Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.